Marchildon Patrice A, Sugiyama Toshiro, Fukuda Yoshihiro, Peacock Jeffrey S, Asaka Masahiro, Shimoyama Takashi, Graham David Y
Enteric Products, Inc., Stony Brook, New York, USA.
J Clin Microbiol. 2003 Apr;41(4):1480-5. doi: 10.1128/JCM.41.4.1480-1485.2003.
It has been suggested that enzyme immunoassay (EIA) kits validated in one region may yield variable diagnostic performance results in different regions, possibly due to strain-specific differences in antibody responses in different populations. We tested (13)C-urea breath test-characterized serum samples from 109 U.S. patients and 288 Japanese patients using enzyme immunoassay with different preparations of high-molecular-weight cell-associated (HM-CAP) antigens that are conserved across Helicobacter pylori strains. Replicate antigens were prepared from five H. pylori clinical isolates. Eight antigen preparations were evaluated: two of U.S. origin and six of Japanese origin. The accuracies achieved with the eight antigen preparations ranged from 94.4 to 96.3% with the U.S. samples. With the Japanese samples the accuracies achieved ranged from 92.3 to 97.2%. Use of a pool of HM-CAP antigens prepared from isolates from Japan resulted in a higher median enzyme immunoassay value and slightly fewer samples with indeterminate results compared to the results obtained by use of the U.S. standard HM-CAP antigen for H. pylori-positive patients (accuracies, 97.2 and 92.3%, respectively), suggesting that variations in performance between both antigen source and patient population might be reduced by using antigens pooled from several strains.
有人提出,在一个地区经验证的酶免疫分析(EIA)试剂盒在不同地区可能会产生不同的诊断性能结果,这可能是由于不同人群抗体反应的菌株特异性差异所致。我们使用酶免疫分析法,对来自109名美国患者和288名日本患者的经¹³C - 尿素呼气试验表征的血清样本进行检测,所用的抗原是不同制备方法的高分子量细胞相关(HM - CAP)抗原,这些抗原在幽门螺杆菌菌株中是保守的。从五株幽门螺杆菌临床分离株制备了重复抗原。评估了八种抗原制剂:两种源自美国,六种源自日本。对于美国样本,八种抗原制剂的准确率在94.4%至96.3%之间。对于日本样本,准确率在92.3%至97.2%之间。与使用美国标准的幽门螺杆菌HM - CAP抗原相比,使用从日本分离株制备的HM - CAP抗原池导致幽门螺杆菌阳性患者的酶免疫分析值中位数更高,结果不确定的样本略少(准确率分别为97.2%和92.3%),这表明通过使用从多个菌株汇集的抗原,抗原来源和患者群体之间的性能差异可能会减少。